This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Terbutaline Poses Severe Risks to Pregnant Women, Says FDA
Boxed Warning, Contraindication to Be Added to Asthma Drug's Label
By News Staff
However, new safety information reviewed by the FDA indicates that death and serious adverse reactions, including increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia, have been reported after prolonged administration of oral and injectable terbutaline to pregnant women.
In a Feb. 17 safety alert, the FDA acknowledged that administering terbutaline by injection to a pregnant women in urgent obstetrical situations within a hospital setting may be appropriate based on a physician's clinical judgment. However, the agency said terbutaline administered by injection or by continuous infusion pump should not be used beyond 48-72 hours. The agency also emphasized that injectable terbutaline should not be used in the outpatient or home setting.
Furthermore, the FDA said oral terbutaline is contraindicated for the treatment or prevention of preterm labor because it has not been shown to be effective and has safety concerns similar to those associated with the injectable form of the drug.
The agency advised that women who are taking terbutaline for asthma or other medical conditions should talk with their physician if they are pregnant or become pregnant to determine whether use of the drug should be discontinued.
The FDA also encouraged physicians to report adverse events involving terbutaline to the agency's MedWatch program.
American Family Physician: "Cochrane for Clinicians: Are Oral Betamimetics Effective Maintenance Therapies After Threatened Preterm Labor?"
FDA: Terbutaline Information